이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

브라질 건강한 성인을 대상으로 한 에프수바글루타이드 알파의 브리징 연구 (BRIDGE-BR)

2026년 11월 17일 업데이트: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

브라질 건강한 성인 참가자를 대상으로 Efsubaglutide Alfa의 안전성, 약동학 및 약력학을 평가하기 위한 무작위, 이중맹검, 위약대조 브리징 연구

This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011. Participants will be randomized to receive a single subcutaneous dose of YN-011 1 mg, YN-011 3 mg, or matching placebo. The study includes screening, approximately 2 days of study-site confinement from the day before dosing to 24 hours after dosing, and outpatient follow-up for 4 weeks. Assessments include safety monitoring, PK blood sampling, PD evaluations, and immunogenicity testing.

연구 개요

상태

빼는

정황

개입 / 치료

상세 설명

This is a Phase I, randomized, double-blind, placebo-controlled, single-dose, parallel-group study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011 following subcutaneous administration.

The study will be conducted at a single clinical study site in Brazil and will enroll approximately 48 healthy adult participants. Participants will be randomized into 2 dose cohorts, a 1 mg cohort and a 3 mg cohort. Within each cohort, participants will be randomized in a 5:1 ratio to receive a single subcutaneous dose of YN-011 or matching placebo. Overall, the study will include 3 treatment groups: YN-011 1 mg, YN-011 3 mg, and placebo. The placebo will be matched in appearance and administered using the same device format in order to maintain blinding.

The main objectives of the study are to assess the safety and tolerability of YN-011 after single-dose administration in healthy adult participants, to characterize its PK profile, to evaluate selected PD effects, and to assess immunogenicity. Safety evaluations will include adverse events, clinical laboratory tests, vital signs, electrocardiograms, physical examinations, and other appropriate clinical assessments. PK assessments will characterize the concentration-time profile of YN-011 after dosing. PD assessments will evaluate the biologic effects of YN-011 after administration. Immunogenicity assessments will evaluate whether participants develop an immune response to YN-011.

The study includes a screening period of up to 4 weeks, a study-site confinement period of approximately 2 days, and an outpatient follow-up period of 4 weeks, for a maximum total study duration of approximately 8 weeks per participant. Participants will be admitted to the clinical study site on the day before dosing and will undergo pre-dose assessments to confirm continued eligibility. On Day 1, participants will receive a single subcutaneous injection of YN-011 1 mg, YN-011 3 mg, or matching placebo in the abdomen using a prefilled auto-injector.

During the confinement period, participants will remain under close clinical observation and will receive a controlled diet with specified fasting and fluid intake restrictions around dosing. After completion of the post-dose confinement period, participants will be discharged from the clinical study site and will return for scheduled outpatient follow-up visits for PK blood sampling, safety monitoring, PD evaluations, and immunogenicity assessments.

The results of this study are expected to provide clinical information on the safety, PK, PD, and immunogenicity profile of single-dose YN-011 in healthy adult participants in Brazil.

연구 유형

중재적

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • São Paulo
      • Valinhos, São Paulo, 브라질, 13271-130
        • A2Z Clinical Centro Avançado de Pesquisa Clínica LTDA

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Healthy male or female adults, aged 18-45 years (both inclusive) at the time of signing the informed consent form (ICF).
  2. Body mass index (BMI) between 18-28 kg/m2 (both inclusive). Male participants must weigh no less than 50 kg, and female participants must weigh no less than 45 kg.
  3. Voluntary participation in this study, as documented by the written signature of two copies of the ICF.
  4. Negative serum pregnancy test for women of childbearing potential (WOCBP) during screening period. WOCBP and fertile male participants with WOCBP partners must use highly effective contraception methods without planning to become pregnant or to donate sperm or eggs throughout this study (from signing the ICF to at least 3 months after completion of this study).
  5. Be able to maintain good communication with the investigators and comply with all requirements of protocol to complete all trial procedures.

Exclusion Criteria:

  1. Known or suspected allergy to the investigational medicinal product, its components or drugs of the same class, or a clinically significant drug allergy, or a history of atopic allergic disease.

  2. Previously or currently diagnosed diabetes mellitus (T1D or T2D) or prediabetes, according to the diagnostic criteria of the Brazilian Diabetes Society (SBD) guideline, defined by any of the following laboratory findings:

    • FPG ≥126 mg/dL or ≥7.0 mmol/L ;
    • FPG 100-125 mg/dL or 5.6 -6.9 mmol/L (prediabetes);
    • HbA1c ≥ 6.5% or ≥48 mmol/mol;
    • HbA1c 5.7-6.4% or 39-47 mmol/mol (prediabetes).
  3. History of clinically significant endocrine disorders that may affect glucose metabolism, body weight, or drug PK, including but not limited to Cushing's syndrome; acromegaly; pheochromocytoma; untreated or uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism); polycystic ovary syndrome (PCOS) with metabolic abnormalities; adrenal insufficiency or other adrenal disorders; pituitary disorders affecting hormonal regulation.

  4. History of acute or chronic pancreatitis, symptomatic gallbladder disease (those who have recovered from cholecystectomy and have no sequelae after treatment are allowable to be enrolled), pancreatic injury or other high-risk factors that may lead to pancreatitis, or screening serum amylase or lipase >2X upper limit of normal (ULN).

  5. History of significant gastrointestinal (GI) disorders (e.g., gastroparesis, active ulcers within 6 months, or long-term use of medications that directly affect GI motility, or GI surgery within 6 months prior to screening.

  6. History or presence of hepatic, renal, cardiovascular, neurological, psychiatric, psychological or immunological disorders.

  7. Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or 12-lead ECG at screening, and investigators consider that these abnormalities may affect participant's safety or study results. ECG abnormalities including but not limited to: second- or third-degree atrioventricular block; long QT syndrome or QTcF > 450 ms (males) or > 470 ms (females). (If the QTcF > 450 ms (males) or > 470 ms (females), two additional ECG measurements should be repeated, and the mean of the three values should be used to determine the participant's eligibility.); left bundle branch block;Wolff-Parkinson-White syndrome; Or other clinically significant 12-lead ECG abnormalities requiring treatment.

  8. Use of any prescription or over-the-counter (OTC) medications, traditional Chinese medicine within 12 months prior to screening that may confound PK, PD, or safety assessments.

  9. Personal or family history of thyroid C-cell tumors including medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia type 2 (MEN2), or presence of hyperthyroidism or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for at least 3 months or longer).

  10. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBSAg) and HBV-deoxyribonucleric adic (DNA) ≥ lab-specific ULN (for those with positive result on HBsAg, HBV-DNA test will be performed), hepatitis C antibody (HCV-Ab) and HCV-ribonucleric acid (RNA), participant can be eligible at the discretion of the investigator if HCV-Ab positive and HCV RNA negative, or Treponema pallidum antibody (TP-Ab).

  11. Pregnant or breastfeeding women.

  12. Donation or loss of ≥400 mL of blood within 3 months prior to screening.

  13. History of drug abuse within 1 year prior to screening, or positive drug abuse screening test (including amphetamines (AMP), cocaine (COC), tetrahydrocannabinol (THC), morphine (MOP), benzodiazepines (BZO), and methamphetamines (MET), any one or more of which tested positive).

  14. Consumption of more than 14 units of alcohol per week within 6 months prior to screening (1 unit of alcohol equivalent to 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine), or consumption of alcohol-containing products within 48 hours before administration, or positive breath alcohol test before administration.

  15. Participation in other clinical trials of vaccines, medical devices, or other drugs within 12 months prior to screening

  16. Major surgery within 4 weeks prior to screening, or planned major surgery during the study.

  17. Participant with systolic blood pressure (SBP) < 90 mmHg or > 140 mmHg, or diastolic blood pressure (DBP) < 50 mmHg or > 90 mmHg after resting in a sitting position, or heart rate (HR) < 50 beats per minute (BPM) or > 100 bpm at rest in sitting position at the screening.

  18. Any other factors that may affect participation in this study at the discretion of the investigator.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약

Matching placebo will be administered as a single subcutaneous injection on Day 1 in healthy adult participants. Placebo is identical in appearance and presentation to efsubaglutide alfa and will be administered in the abdomen using a matching prefilled auto-injector.

실험적: YN-011 1mg

Efsubaglutide alfa will be administered as a single subcutaneous injection at a dose of 1 mg or 3 mg on Day 1 in healthy adult participants. The study drug will be administered in the abdomen using a prefilled auto-injector.

실험적: YN-011 3mg

Efsubaglutide alfa will be administered as a single subcutaneous injection at a dose of 1 mg or 3 mg on Day 1 in healthy adult participants. The study drug will be administered in the abdomen using a prefilled auto-injector.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
YN-011의 말단제거 반감기(t1/2)
기간: 투약 전부터 29일까지
투약 전부터 29일까지
Concentration (Cmax) of YN-011 maximum Observed Plasma
기간: Predose through Day 29
Predose through Day 29
Concentration (Tmax) of YN-011 Time to Maximum Observed Plasma
기간: Predose through Day 29
Predose through Day 29
Concentration (AUC0-t) of YN-011 Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable
기간: Predose through Day 29
Predose through Day 29
Concentration of Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011
기간: Predose through Day 29
Predose through Day 29

2차 결과 측정

결과 측정
측정값 설명
기간
YN-011의 AUC0-inf와 제29일 공복 혈장 포도당의 기준선 대비 변화 간의 상관관계
기간: 기준선 및 29일차
기준선 및 29일차
YN-011의 AUC0-inf와 29일째 체중 변화(기저선 대비) 간의 상관관계
기간: 기준선 및 29일차
기준선 및 29일차
Rate of Incidence and severity of adverse events
기간: From informed consent through Day 29

Incidence and severity of adverse events, including treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

From informed consent through Day 29
Rate of Clinically significant changes in vital signs, clinical laboratory tests, and 12-lead electrocardiograms
기간: Baseline through Day 29

Clinically significant changes in vital signs, clinical laboratory tests, including hematology, biochemistry, amylase, lipase, and urinalysis, and 12-lead electrocardiograms.

Baseline through Day 29
Change rate of from baseline in fasting plasma glucose
기간: Baseline through Day 29
Baseline through Day 29
Change Rate of From Baseline in Body Weight
기간: Baseline through Day 29
Baseline through Day 29
Incidence rate of anti-drug antibodies and neutralizing antibodies
기간: Baseline through Day 29

Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs), if ADA positive.

Baseline through Day 29
Comparison of AUC0-inf of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
기간: Predose through Day 29

Comparison of AUC0-inf of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.

Predose through Day 29
Comparison of AUC0-t of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
기간: Predose through Day 29

Comparison of AUC0-t of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.

Predose through Day 29
Comparison of Cmax of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
기간: Predose through Day 29

Comparison of Cmax of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.

Predose through Day 29

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 1일

기본 완료 (추정된)

2026년 8월 1일

연구 완료 (추정된)

2026년 10월 31일

연구 등록 날짜

최초 제출

2026년 3월 26일

QC 기준을 충족하는 최초 제출

2026년 4월 1일

처음 게시됨 (실제)

2026년 4월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • YN011-I-102-BR

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .